Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus. Reviewed

Li J, Liu JK, Chau A, Linden S, Tsai PC, Nozaki A, Vutien P, Uojima H, Toyoda H, Honda T, Trinh H, Abe H, Ishikawa T, Atsukawa M, Watanabe T, Tsuji K, Huang DQ, Takaguchi K, Itobayashi E, Marciano S, Rui F, Ni W, Takahashi H, Chuang WL, Dai CY, Huang JF, Huang CF, Yeh ML, Zhu Y, Itokawa N, Kozuka R, Inoue K, Senoh T, Maeda M, Ito T, Morimoto M, Cheung R, Gadano A, Enomoto M, Tanaka Y, Lim SG, Wu C, Yu ML, Nguyen MH.

Am J Gastroenterol   2025.12

Differential HCC risk among HBV indeterminate types at baseline and by phase transition Reviewed

Huang R, Trinh HN, Yasuda S, Chau A, Maeda M, Do AT, Huang DQ, Ito T, Honda T, Ishigami M, Kozuka R, Preda CM, Tseng CH, Marciano S, Tsai PC, Lee DH, Wong CC, Do S, Kawashima K, Zhang J, Marin RI, Sandra I, Li J, Ogawa E, Cheung R, Li J, Yu ML, Gadano A, Hsu YC, Buti M, Enomoto M, Lim SG, Wu C, Toyoda H, Nguyen MH.

Gut   2025.10

Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs. Reviewed

Chau A, Li J, Jun DW, Hsu YC, Toyoda H, Yeh ML, Watanabe T, Honda T, Trinh H, Nozaki A, Uojima H, Ishikawa T, Huang DQ, Vutien P, Marciano S, Abe H, Atsukawa M, Enomoto M, Takahashi H, Tsuji K, Takaguchi K, Itobayashi E, Huang R, Tsai PC, Dai CY, Huang JF, Huang CF, Yoon E, Kim SE, Ahn SB, Kim GA, Jung JH, Jeong SW, Oh H, Hsiao T, Maeda M, Tseng CH, Yasuda S, Ishigami M, Chuma M, Ito T, Kawashima K, Liu JK, Itokawa N, Kozuka R, Inoue K, Senoh T, Chuang WL, Gadano A, Tanaka Y, Lim SG, Wu C, Cheung R, Yu ML, Nguyen MH.

Journal of viral hepatitis   2025.10

Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Reviewed

Huang R, Jun DW, Toyoda H, Hsu YC, Trinh H, Nozaki A, Ishikawa T, Watanabe T, Uojima H, Huang DQ, Honda T, Tanaka Y, Vutien P, Marciano S, Abe H, Enomoto M, Atsukawa M, Takahashi H, Tsuji K, Itobayashi E, Takaguchi K, Tsai PC, Dai CY, Huang JF, Huang CF, Yeh ML, Yoon E, Kim SE, Ahn SB, Kim GA, Jung JH, Jeong SW, Oh H, Tseng CH, Ishigami M, Chau A, Hsiao T, Maeda M, Yasuda S, Chuma M, Ito T, Kawashima K, Liu JK, Gadano A, Kozuka R, Itokawa N, Inoue K, Senoh T, Li J, Chuang WL, Cheung R, Wu C, Yu ML, Nguyen MH.

EClinicalMedicine   2025.08

Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B Study. Reviewed

Huang R, Do AT, Toyoda H, Li J, Yasuda S, Tsai PC, Yeh ML, Trinh H, Chau A, Huang DQ, Ogawa E, Ito T, Kozuka R, Atsukawa M, Marciano S, Honda T, Watanabe T, Itokawa N, Preda CM, Tseng CH, Barreira A, Inoue K, Takahashi H, Uojima H, Kawashima K, Hsu YC, Marin RI, Sandra I, Ishigami M, Li J, Zhang J, Do S, Maeda M, Lee DH, Chuang WL, Dai CY, Huang JF, Huang CF, Cheung R, Buti M, Tanaka Y, Yuen MF, Enomoto M, Gadano A, Lim SG, Yu ML, Wu C, Nguyen MH.

Alimentary Pharmacology and Therapeutics   2025.08

Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation. Reviewed

Suzuki T, Tamori A, Matsuura K, Inoue T, Kusumoto S, Hagiwara S, Sagi H, Kaneko A, Murakami S, Kawamra H, Fujiwara K, Aoyagi K, Enomoto M, Kozuka R, Kataoka H, Tanaka Y.

Ann Hepatol   2025.01

Predictors of Immediate Deterioration of the Child-Pugh Classification From A to B After Transcatheter Arterial Chemo-Embolization for Treatment-Naive Hepatocellular Carcinoma. Reviewed

Asano K, Kageyama K, Yamamoto A, Jogo A, Nakano M, Murai K, Yukawa-Muto Y, Odagiri N, Kotani K, Kozuka R, Kawamura E, Fujii H, Uchida-Kobayashi S, Enomoto M, Kawada N, Miki Y.

Cancer Med   2024.11

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study

Ji F.

Journal of Clinical and Translational Hepatology   12 ( 7 )   646 - 658   2024.07（ ISSN:22250719 ）

Sex and ethnic disparities in hepatitis B evaluation and treatment across the world

Kudaravalli S.

Journal of Hepatology   81 ( 1 )   33 - 41   2024.07（ ISSN:01688278 ）

Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy Reviewed

2024.07 （ ISSN:13866346 ）

Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study

Jang T.Y.

Journal of Gastroenterology and Hepatology (Australia)   39 ( 6 )   1190 - 1197   2024.06（ ISSN:08159319 ）

Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs

Jang T.Y.

Kaohsiung Journal of Medical Sciences   40 ( 2 )   188 - 197   2024.02（ ISSN:1607551X ）

肝炎医療コーディネーターと連携した非専門医科のHCV抗体陽性者に対する効率的な個別勧奨 Reviewed

小塚 立蔵, 榎本 大, 藤井 英樹, 打田（小林） 佐和子, 河田 則文, 是永 匡紹

肝臓   2024

Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase Reviewed

Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH.

Hepatology   2023.11

Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort

Kozuka R.

Journal of Viral Hepatitis   30 ( 5 )   374 - 385   2023.05（ ISSN:13520504 ）

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis. Reviewed

Kotani K, Enomoto M, Uchida-Kobayashi S, Tamori A, Yukawa-Muto Y, Odagiri N, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Kageyama K, Yamamoto A, Yoshida A, Higashiyama S, Kawabe J, Kawada N.

Journal of Gastroenterology   2023.04

Severity of Liver Fibrosis Is Associated with the Japanese Diet Pattern and Skeletal Muscle Mass in Patients with Nonalcoholic Fatty Liver Disease. Reviewed

Matsumoto Y, Fujii H, Harima M, Okamura H, Yukawa-Muto Y, Odagiri N, Motoyama H, Kotani K, Kozuka R, Kawamura E, Hagihara A, Uchida-Kobayashi S, Enomoto M, Yasui Y, Habu D, Kawada N.

Nutrients   2023.02

Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. Reviewed

Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, Toyoda H, Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH.

Hepatol Int   2022.12

Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21. Reviewed

Kawamura E, Matsubara T, Daikoku A, Deguchi S, Kinoshita M, Yuasa H, Urushima H, Odagiri N, Motoyama H, Kotani K, Kozuka R, Hagihara A, Fujii H, Uchida-Kobayashi S, Tanaka S, Takemura S, Iwaisako K, Enomoto M, Taguchi YH, Tamori A, Kubo S, Ikeda K, Kawada N.

FEBS Open Bio   2022.12

Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. Reviewed

Uchida-Kobayashi S, Kageyama K, Takemura S, Matsumoto K, Odagiri N, Jogo A, Kotani K, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Yamamoto A, Fujii H, Tanaka S, Enomoto M, Tamori A, Miki Y, Kubo S, Kawada N.

JGH Open   2022.09

Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.

Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.

Clin Gastroenterol Hepatol   2022.04

Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Reviewed

Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH.

Hepatol Int   2022.02

Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. Reviewed

Kozuka R, Enomoto M, Dong MP, Hai H, Thuy LTT, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Tamori A, Kawada N.

Sci Rep   2022.01

Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. Reviewed

Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N.

Journal of Viral Hepatitis   2022.01

On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Reviewed

Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML.

Liver Int   2022.01

Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. Reviewed

Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, Enomoto M, Xie Q, Trinh H, Preda C, Liu L, Cheung KS, Yeo YH, Hoang J, Huang CF, Riveiro-Barciela M, Kozuka R, Istratescu D, Tsai PC, Accarino EV, Lee DH, Wu JL, Huang JF, Dai CY, Cheung R, Chuang WL, Yuen MF, Wong VW, Yu ML, Nguyen MH.

J Infect Dis   2021.12

Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation. Reviewed

Tamori A, Kimura K, Kioka K, Enomoto H, Odagiri N, Kozuka R, Uchida-Kobayashi S, Enomoto M, Kawada N, Mizokami M.

J Med Virol   2021.06

Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Reviewed

Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.

Hepatol Int   2021.02

Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. Reviewed

Kikukawa K, Uchida-Kobayashi S, Tamori A, Yoshida K, Kotani K, Motoyama H, Kozuka R, Hagihara A, Fujii H, Morikawa H, Enomoto M, Murakami Y, Kawada N.

Ann Hepatol   2020.07

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. Reviewed

Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N.

JGH Open   2020.06

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.

Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH.

Am J Gastroenterol   2020.02

Development of a novel anti-hepatitis B virus agent via Sp1. Reviewed

Hayakawa M, Umeyama H, Iwadate M, Taguchi YH, Yano Y, Honda T, Itami-Matsumoto S, Kozuka R, Enomoto M, Tamori A, Kawada N, Murakami Y.

Sci Rep   2020.01

Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. Reviewed

Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH.

J Infect Dis   2020.01

Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. Reviewed

Iida-Ueno A, Enomoto M, Kozuka R, Tamori A, Kawada N.

J Med Virol   2019.07

Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment. Reviewed

Kozuka R, Enomoto M, Sato-Matsubara M, Yoshida K, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Tamori A, Kawada N, Murakami Y.

J Gastroenterol Hepatol   2019.05

Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. Reviewed

Enomoto M, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Murakami Y, Kawada N.

United European Gastroenterol J   2018.11

The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. Reviewed

Kozuka R, Hai H, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A.

J Viral Hepat   2018.05

Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. Reviewed

Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Fujii H, Uchida-Kobayashi S, Fukunishi S, Tsuda Y, Higuchi K, Saito M, Enomoto H, Kawada N.

Hepatology Research   2018.05

Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradicatio Reviewed

Motoyama H, Tamori A, Kubo S, Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N.

PLoS One   2018.03

Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. Reviewed

Tamori A, Hai H, Uchida-Kobayashi S, Enomoto M, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Teranishi Y, Yoshida K, Morikawa H, Murakami Y, Kawada N.

Ann Hepatol   2017.09

Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. Reviewed

Kozuka R, Hai H, Teranishi Y, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A.

J Gastroenterol Hepatol   2017.08

Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed. Reviewed

Yoshida K, Hai H, Tamori A, Teranishi Y, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N.

Int J Mol Sci   2017.05

Direct-acting antivirals治療例におけるC型肝炎ウイルス感染経路の検討―再感染リスクを踏まえ Reviewed

湯川 芳美, 田守 昭博, 寺西 優雅, 元山 宏行, 小塚 立蔵, 川村 悦史, 萩原 淳司, 打田（小林） 佐和子, 森川 浩安, 榎本 大, 村上 善基, 福島 若葉, 河田 則文

肝臓   2017

Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1 Reviewed

Tamori A, Yoshida K, Kurai O, Kioka K, Hai H, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N.

Hepatology Research   2016.12

当院における肝炎ウイルス検査の実施状況と陽性者に対する受診勧奨システム構築による院内連携の変化について Reviewed

打田（小林） 佐和子, 榎本 大, 藤井 英樹, 飯田（上野） 綾子, 元山 宏行, 小塚 立蔵, 萩原 淳司, 川村 悦史, 森川 浩安, 村上 善基, 田守 昭博, 河田 則文

肝臓   2016

Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. Reviewed

Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Hayashi T, Kohmoto MT, Jomura H, Morikawa H, Murakami Y, Shiomi S, Kawada N.

J Interferon Cytokine Res   2015.08

Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use. Reviewed

Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, Saito S, Kawada N.

Hepatology Research   2013.10

Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment. Reviewed

Kozuka R, Enomoto M, Hai H, Ogawa T, Nakaya M, Hagihara A, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Kawada N.

Hepatology Research   2012.12

Anti-hepatitis B virus therapy: To stop, or not to stop: Has the question been solved? Reviewed

Kozuka R, Enomoto M, Morikawa H, Tamori A, Kawada N.

Hepatology Research   2012.09

各種治療に抵抗性を示した自己免疫性肝炎の1例 Reviewed International journal

小塚 立蔵, 岩井 秀司, 遠山 まどか, 藤井 英樹, 安田 隆弘, 小林 佐和子, 黒岡 浩子, 中山 祐史, 榎本 大, 森川 浩安, 田守 昭博, 坂口 浩樹, 河田 則文

2009

B型肝炎診療Cutting edge　ウイルスマーカーから見たPegIFN開始後の長期経過におけるHBsAg陰性化予測

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

若年男性に発症し寛解再燃を認めた放線菌感染症による肝膿瘍の1例

小谷 晃平, 津田 真穂, 池永 寛子, 武藤 芳美, 小田桐 直志, 元山 宏行, 小塚 立蔵, 川村 悦史, 藤井 英樹, 打田 佐和子, 榎本 大, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

BCLC stage 0&A HCC治療においてBCLC strategy 2022 updateで推奨されたTACE治療効果の検討　単発の初発未治療肝細胞癌73症例73結節の局所制御について

影山 健, 山本 晃, 池永 寛子, 武藤 芳美, 小田桐 直志, 小谷 晃平, 小塚 立蔵, 川村 悦史, 藤井 英樹, 打田 佐和子, 榎本 大, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

Phase Angleを用いた慢性肝疾患患者におけるサルコペニア評価の意義

元山 宏行, 池永 寛子, 武藤 芳美, 小田桐 直志, 小谷 晃平, 小塚 立蔵, 川村 悦史, 藤井 英樹, 打田 佐和子, 榎本 大, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

新任肝炎医療コーディネーターによる肝がん・重度肝硬変治療研究促進事業活用のための患者サポート

星野 実果, 中井 香奈子, 榎本 大, 池永 寛子, 武藤 芳美, 小田桐 直志, 小谷 晃平, 元山 宏行, 小塚 立蔵, 川村 悦史, 萩原 淳司, 藤井 英樹, 打田 佐和子, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

肝炎医療コーディネーター主導によるポストコロナ参加型肝炎デーイベントの開催

中井 香奈子, 星野 実果, 榎本 大, 池永 寛子, 武藤 芳美, 小田桐 直志, 小谷 晃平, 元山 宏行, 小塚 立蔵, 川村 悦史, 萩原 淳司, 藤井 英樹, 打田 佐和子, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

肝細胞癌に対する短期LEN導入後TACE sequential therapyの有効性と安全性の検討

打田 佐和子, 小田桐 直志, 池永 寛子, 武藤 芳美, 小谷 晃平, 小塚 立蔵, 元山 宏行, 影山 健, 新川 寛二, 川村 悦史, 萩原 淳司, 山本 晃, 藤井 英樹, 榎本 大, 河田 則文

肝臓  2024.04  (一社)日本肝臓学会

C型肝炎治癒後の長期マネージメント　DAA治療後SVR例におけるTransient elastographyを用いた線維化進展度別の肝発癌リスク因子の検討

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2023.10  (一社)日本肝臓学会

多種職連携による非専門科の陽性者の拾い上げと効率的な個別勧奨の試み

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2023.09  (一社)日本肝臓学会

B型肝炎診療の未来予想図(現状と課題)　核酸アナログ開始後の肝発癌リスク因子　新規糖鎖マーカーHBsAgGiを含め

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2023.04  (一社)日本肝臓学会

Transient elastographyを用いた非高度肝線維化例におけるSVR後の肝発癌リスク因子の検討

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2023.04  (一社)日本肝臓学会

C型肝炎制御下での諸問題と治療戦略　実臨床でのDAA治療によるHCV制御下の生命予後に寄与する因子の検討

小塚 立蔵, 田守 昭博, 河田 則文

肝臓  2022.09  (一社)日本肝臓学会

PegIFN治療後の長期経過におけるHBsAg陰性化予測因子の検討

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2022.09  (一社)日本肝臓学会

門脈圧亢進症は改善するか?　非代償性まで含めたC型肝硬変に対するDAA治療後SVR例における生命予後の検討

小塚 立蔵, 榎本 大, 武藤 芳美, 小田桐 直志, 小谷 晃平, 元山 宏行, 川村 悦史, 萩原 淳司, 藤井 英樹, 打田 佐和子, 河田 則文

日本門脈圧亢進症学会雑誌  2022.08  (一社)日本門脈圧亢進症学会

肝疾患におけるバイオマーカー研究　核酸アナログ開始後のHBs抗原量の低下を予測する因子の検討　宿主遺伝子多型も含めて

小塚 立蔵, 榎本 大, 河田 則文

肝臓  2022.04  (一社)日本肝臓学会

B型肝炎:研究と診療の最前線　PegIFN治療後の長期経過におけるHBs抗原陰性化例の特徴

小塚 立蔵, 榎本 大, 河田 則文

日本消化器病学会雑誌  2022.03  (一財)日本消化器病学会

B型慢性肝炎に対するfunctional cureに向けたPegIFNの長期成績　両立支援の重要性を含め

小塚 立蔵, 榎本 大, 武藤 芳美, 小田桐 直志, 小谷 晃平, 元山 宏行, 川村 悦史, 萩原 淳司, 藤井 英樹, 打田 佐和子, 田守 昭博, 河田 則文

肝臓  2021.11  (一社)日本肝臓学会

肝炎ウイルス制御下の発癌と諸問題　可溶性免疫チェックポイント分子から見た核酸アナログによるHBV制御後の肝発癌危険因子の検討

小塚 立蔵, Le Thi Thanh Thuy, 河田 則文

肝臓  2021.04  (一社)日本肝臓学会

B型肝炎での血清エクソソーム中マイクロRNAを用いた新規肝発癌予測マーカーの開発

Grant-in-Aid for Early-Career Scientists  2019

B型肝炎での血清エクソソーム中マイクロRNAを用いた新規肝発癌予測マーカーの開発

Grant-in-Aid for Early-Career Scientists  2018

肝発癌例での次世代シークエンサーを用いたHBV遺伝子変異と宿主遺伝子多型の解析

Grant-in-Aid for Young Scientists(B)  2016

肝発癌例での次世代シークエンサーを用いたHBV遺伝子変異と宿主遺伝子多型の解析

Grant-in-Aid for Young Scientists(B)  2015

臨床医科学（肝胆膵病態内科学）

2025   Intensive lecture   Graduate school

肝胆膵病態内科学（総論）

2025   Intensive lecture   Graduate school

肝胆膵病態内科学（肝感染症学特論）

2025   Intensive lecture   Graduate school